Glucagon-like Peptide-1
Glucagon-like Peptide-1 - Related Videos
01:15
Hypoglycemia and Glucagon
0 Views •
2024
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24
Glucagon-like Receptor Agonists
0 Views •
2024
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP. GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
14:44
Structure and Coordination Determination of Peptide-metal Complexes Using 1D and 2D 1H NMR
0 Views •
Cited by 4 •
2013
The NMR-solution structure of a metallochaperone model peptide with Cu (I) was determined, and a detailed protocol from sample preparation and 1D and 2D data collection to a three-dimensional structure is described.
08:04
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
0 Views •
Cited by 4 •
2017
Qa-1 (HLA-E in human) belongs to a group of non-classical major histocompatibility complex 1b molecules. Immunization with Qa-1-binding epitopes has been shown to augment tissue-specific immune regulation and ameliorate several autoimmune diseases. Herein we describe an overlapping peptide library strategy for the identification of Qa-1 epitopes in a protein.
04:00
Immunoaffinity Based Extraction of Ubiquitinylated Peptides: A Technique to Selectively Extract Ubiquitin Tagged Peptides from Purified Peptide Fractions
0 Views •
2023
This video describes a method to extract and purify ubiquitinylated peptides containing remnant di-glycine peptides from a complex peptide mixture. The presented method may help in identifying original ubiquitination sites in the protein.
FAQs
Activation of the GLP-1 receptor, a G protein-coupled receptor, links hormone signaling to several physiological outputs. In pancreatic regulation, it enhances insulin secretion when blood glucose is elevated and suppresses glucagon release. This receptor-level coupling explains why one signal can coordinate glucose control with digestive and appetite-related effects.
Glucose dependence means that GLP-1 signaling enhances insulin secretion in the context of elevated blood glucose rather than acting independently of glucose conditions. This feature connects receptor activation directly to meal-related glucose regulation. It also distinguishes the hormone’s action from a generalized stimulation of insulin release and helps explain its pharmacological relevance in type 2 diabetes.
The effects on gastric emptying and satiety extend GLP-1 activity beyond pancreatic glucose regulation. Slower gastric emptying can influence how food-related signals reach the metabolic system, while increased satiety affects appetite and energy intake. Together, these actions help explain why GLP-1 signaling is relevant to both blood-glucose control and obesity-focused pharmacology.
GLP-1 receptor agonists are pharmacological agents designed to extend the actions associated with naturally released GLP-1. Rather than serving only as a transient post-meal signal, they provide a therapeutic way to activate the same receptor pathway. This distinction allows clinicians and researchers to apply GLP-1 biology in treating type 2 diabetes and obesity.
GLP-1 receptor agonists are used to treat type 2 diabetes and obesity because their receptor-mediated effects address several relevant processes at once. Their actions include glucose-dependent enhancement of insulin secretion, glucagon suppression, slower gastric emptying, and greater satiety. The combination makes this drug class relevant when metabolic regulation and energy balance are both clinical concerns.
Studies of GLP-1-based therapies can evaluate changes in blood-glucose regulation, appetite, and energy balance, while also examining the coordinated effects of receptor activation on insulin, glucagon, and gastric emptying. These outcomes connect molecular pharmacology with whole-body physiology. They also help assess how effectively an agonist reproduces the therapeutically useful actions of GLP-1.
Glucagon-like Peptide-1 provides a model for studying how gut-derived hormonal signals can be translated into therapies for metabolic disease. Its receptor connects post-meal signaling with pancreatic, gastrointestinal, and appetite-related responses. In pharmacology, this framework supports ongoing development aimed at treating cardiometabolic disease through targeted modulation of metabolic signaling.